{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:10:24Z","timestamp":1782785424522,"version":"3.54.5"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1163327"],"award-info":[{"award-number":["OPP1163327"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201239"],"award-info":[{"award-number":["OPP1201239"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI141236"],"award-info":[{"award-number":["R01AI141236"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI142777"],"award-info":[{"award-number":["U19 AI142777"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antibody immunotherapy is revolutionizing modern medicine. The field has advanced dramatically over the past 40\u00a0years, driven in part by major advances in isolation and manufacturing technologies that have brought these important biologics to the forefront of modern medicine. However, the global uptake of monoclonal antibody (mAb) biologics is impeded by biophysical and biochemical liabilities, production limitations, the need for cold-chain storage and transport, as well as high costs of manufacturing and distribution. Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. These approaches turn the body into a biological factory for antibody production, eliminating many of the steps involved in bioprocesses and providing several other significant advantages, and differ from traditional gene therapy (permanent delivery) approaches. In this review, we focus on nucleic acid delivery of antibody employing synthetic plasmid DNA vector platforms, and RNA delivery, these being important approaches that are advancing simple, rapid, in vivo expression and having an impact in animal models of infectious diseases and cancer, among others.<\/jats:p>","DOI":"10.1007\/s40259-020-00412-3","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T12:02:52Z","timestamp":1583841772000},"page":"273-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-9984","authenticated-orcid":false,"given":"Ami","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-1085","authenticated-orcid":false,"given":"Mamadou A.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"issue":"2","key":"412_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182\u201321212. https:\/\/doi.org\/10.1080\/19420862.2016.1268307.","journal-title":"MAbs"},{"key":"412_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-981-13-0502-3_8","volume":"1068","author":"A Voigt","year":"2018","unstructured":"Voigt A, Semenova T, Yamamoto J, Etienne V, Nguyen CQ. Therapeutic antibody discovery in infectious diseases using single-cell analysis. Adv Exp Med Biol. 2018;1068:89\u2013102. https:\/\/doi.org\/10.1007\/978-981-13-0502-3_8.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"412_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nbt.1791","volume":"29","author":"AR Bradbury","year":"2011","unstructured":"Bradbury AR, Sidhu S, Dubel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol. 2011;29(3):245\u201354. https:\/\/doi.org\/10.1038\/nbt.1791.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"412_CR4","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1007\/s00253-016-7388-9","volume":"100","author":"R Kunert","year":"2016","unstructured":"Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451\u201361. https:\/\/doi.org\/10.1007\/s00253-016-7388-9.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"412_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jps.22758","volume":"101","author":"TM Lauer","year":"2012","unstructured":"Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101(1):102\u201315. https:\/\/doi.org\/10.1002\/jps.22758.","journal-title":"J Pharm Sci"},{"key":"412_CR6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1810576116","author":"MIJ Raybould","year":"2019","unstructured":"Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, et al. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci USA. 2019. https:\/\/doi.org\/10.1073\/pnas.1810576116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"412_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","volume":"1","author":"B Kelley","year":"2009","unstructured":"Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009;1(5):443\u201352. https:\/\/doi.org\/10.4161\/mabs.1.5.9448.","journal-title":"MAbs"},{"key":"412_CR8","doi-asserted-by":"publisher","first-page":"e8346","DOI":"10.1136\/bmj.e8346","volume":"345","author":"AF Shaughnessy","year":"2012","unstructured":"Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346. https:\/\/doi.org\/10.1136\/bmj.e8346.","journal-title":"BMJ"},{"issue":"2","key":"412_CR9","first-page":"109","volume":"24","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24(2):109\u201312.","journal-title":"Am J Manag Care"},{"issue":"5","key":"412_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340. https:\/\/doi.org\/10.1007\/s40259-018-0295-0.","journal-title":"BioDrugs"},{"issue":"4","key":"412_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0034-1368173","volume":"74","author":"C Jackisch","year":"2014","unstructured":"Jackisch C, Muller V, Maintz C, Hell S, Ataseven B. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74(4):343\u20139. https:\/\/doi.org\/10.1055\/s-0034-1368173.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"412_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.4","volume":"53","author":"L Zhao","year":"2013","unstructured":"Zhao L, Ji P, Li Z, Roy P, Sahajwalla CG. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314\u201325. https:\/\/doi.org\/10.1002\/jcph.4.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"412_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"412_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87\u2013104. https:\/\/doi.org\/10.1016\/j.omtm.2017.11.007.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"412_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","volume":"9","author":"M Thran","year":"2017","unstructured":"Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui BL, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434\u201347. https:\/\/doi.org\/10.15252\/emmm.201707678.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"412_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334. https:\/\/doi.org\/10.1007\/s40259-017-0234-5.","journal-title":"BioDrugs"},{"key":"412_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","volume":"12","author":"H Buning","year":"2019","unstructured":"Buning H, Srivastava A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev. 2019;12:248\u201365. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.008.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"412_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.virusres.2009.02.010","volume":"143","author":"A Sharma","year":"2009","unstructured":"Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res. 2009;143(2):184\u201394. https:\/\/doi.org\/10.1016\/j.virusres.2009.02.010.","journal-title":"Virus Res"},{"issue":"1","key":"412_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12967-017-1234-4","volume":"15","author":"K Hollevoet","year":"2017","unstructured":"Hollevoet K, Declerck PJ. State of play and clinical prospects of antibody gene transfer. J Transl Med. 2017;15(1):131. https:\/\/doi.org\/10.1186\/s12967-017-1234-4.","journal-title":"J Transl Med"},{"issue":"1","key":"412_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mt.6300344","volume":"16","author":"BP De","year":"2008","unstructured":"De BP, Hackett NR, Crystal RG, Boyer JL. Rapid\/sustained anti-anthrax passive immunity mediated by co-administration of Ad\/AAV. Mol Ther. 2008;16(1):203\u20139. https:\/\/doi.org\/10.1038\/sj.mt.6300344.","journal-title":"Mol Ther"},{"issue":"1","key":"412_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2008.04.016","volume":"378","author":"D Skaricic","year":"2008","unstructured":"Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, et al. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology. 2008;378(1):79\u201385. https:\/\/doi.org\/10.1016\/j.virol.2008.04.016.","journal-title":"Virology"},{"issue":"7379","key":"412_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","volume":"481","author":"AB Balazs","year":"2011","unstructured":"Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481(7379):81\u20134. https:\/\/doi.org\/10.1038\/nature10660.","journal-title":"Nature"},{"issue":"1","key":"412_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12977-018-0449-7","volume":"15","author":"A Lin","year":"2018","unstructured":"Lin A, Balazs AB. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1. Retrovirology. 2018;15(1):66. https:\/\/doi.org\/10.1186\/s12977-018-0449-7.","journal-title":"Retrovirology"},{"issue":"8","key":"412_CR24","doi-asserted-by":"publisher","first-page":"e1005090","DOI":"10.1371\/journal.ppat.1005090","volume":"11","author":"SP Fuchs","year":"2015","unstructured":"Fuchs SP, Martinez-Navio JM, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC. AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog. 2015;11(8):e1005090. https:\/\/doi.org\/10.1371\/journal.ppat.1005090.","journal-title":"PLoS Pathog"},{"issue":"11","key":"412_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1128\/CVI.00572-14","volume":"21","author":"VS Adam","year":"2014","unstructured":"Adam VS, Crosariol M, Kumar S, Ge MQ, Czack SE, Roy S, et al. Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol. 2014;21(11):1528\u201333. https:\/\/doi.org\/10.1128\/CVI.00572-14.","journal-title":"Clin Vaccine Immunol"},{"issue":"187","key":"412_CR26","doi-asserted-by":"publisher","first-page":"187ra72","DOI":"10.1126\/scitranslmed.3006299","volume":"5","author":"MP Limberis","year":"2013","unstructured":"Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med. 2013;5(187):187ra72. https:\/\/doi.org\/10.1126\/scitranslmed.3006299.","journal-title":"Sci Transl Med."},{"issue":"12","key":"412_CR27","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1128\/CVI.00545-13","volume":"20","author":"MP Limberis","year":"2013","unstructured":"Limberis MP, Racine T, Kobasa D, Li Y, Gao GF, Kobinger G, et al. Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9. Clin Vaccine Immunol. 2013;20(12):1836\u20137. https:\/\/doi.org\/10.1128\/CVI.00545-13.","journal-title":"Clin Vaccine Immunol"},{"issue":"6414","key":"412_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","volume":"362","author":"NS Laursen","year":"2018","unstructured":"Laursen NS, Friesen RHE, Zhu X, Jongeneelen M, Blokland S, Vermond J, et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science. 2018;362(6414):598\u2013602. https:\/\/doi.org\/10.1126\/science.aaq0620.","journal-title":"Science"},{"issue":"12","key":"412_CR29","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/infdis\/jiw460","volume":"214","author":"MP Limberis","year":"2016","unstructured":"Limberis MP, Tretiakova A, Nambiar K, Wong G, Racine T, Crosariol M, et al. Adeno-associated virus serotype 9-expressed ZMapp in mice confers protection against systemic and airway-acquired Ebola virus infection. J Infect Dis. 2016;214(12):1975\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiw460.","journal-title":"J Infect Dis"},{"issue":"4","key":"412_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1089\/hum.2017.101","volume":"29","author":"MA Robert","year":"2018","unstructured":"Robert MA, Nassoury N, Chahal PS, Venne MH, Racine T, Qiu X, et al. Gene transfer of ZMapp antibodies mediated by recombinant adeno-associated virus protects against Ebola infections. Hum Gene Ther. 2018;29(4):452\u201366. https:\/\/doi.org\/10.1089\/hum.2017.101.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"412_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12896-017-0365-2","volume":"17","author":"LA Santry","year":"2017","unstructured":"Santry LA, Ingrao JC, Yu DL, de Jong JG, van Lieshout LP, Wood GA, et al. AAV vector distribution in the mouse respiratory tract following four different methods of administration. BMC Biotechnol. 2017;17(1):43. https:\/\/doi.org\/10.1186\/s12896-017-0365-2.","journal-title":"BMC Biotechnol"},{"key":"412_CR32","doi-asserted-by":"publisher","first-page":"794528","DOI":"10.1155\/2015\/794528","volume":"2015","author":"MA McNamara","year":"2015","unstructured":"McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res. 2015;2015:794528. https:\/\/doi.org\/10.1155\/2015\/794528.","journal-title":"J Immunol Res"},{"issue":"12","key":"412_CR33","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1093\/nar\/gkn342","volume":"36","author":"R Juliano","year":"2008","unstructured":"Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008;36(12):4158\u201371. https:\/\/doi.org\/10.1093\/nar\/gkn342.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"412_CR34","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","volume":"13","author":"JJ Suschak","year":"2017","unstructured":"Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother. 2017;13(12):2837\u201348. https:\/\/doi.org\/10.1080\/21645515.2017.1330236.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"412_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/vaccines1030225","volume":"1","author":"JA Williams","year":"2013","unstructured":"Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines (Basel). 2013;1(3):225\u201349. https:\/\/doi.org\/10.3390\/vaccines1030225.","journal-title":"Vaccines (Basel)"},{"key":"412_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2017.09.003","volume":"7","author":"CD Andrews","year":"2017","unstructured":"Andrews CD, Luo Y, Sun M, Yu J, Goff AJ, Glass PJ, et al. In vivo production of monoclonal antibodies by gene transfer via electroporation protects against lethal influenza and Ebola infections. Mol Ther Methods Clin Dev. 2017;7:74\u201382. https:\/\/doi.org\/10.1016\/j.omtm.2017.09.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"412_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","volume":"2","author":"STC Elliott","year":"2017","unstructured":"Elliott STC, Kallewaard NL, Benjamin E, Wachter-Rosati L, McAuliffe JM, Patel A, et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. NPJ Vaccines. 2017;2:18. https:\/\/doi.org\/10.1038\/s41541-017-0020-x.","journal-title":"NPJ Vaccines"},{"issue":"5","key":"412_CR38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ymthe.2019.03.005","volume":"27","author":"RN Esquivel","year":"2019","unstructured":"Esquivel RN, Patel A, Kudchodkar SB, Park DH, Stettler K, Beltramello M, et al. In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus. Mol Ther. 2019;27(5):974\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.005.","journal-title":"Mol Ther"},{"issue":"1","key":"412_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41467-017-00576-7","volume":"8","author":"A Patel","year":"2017","unstructured":"Patel A, DiGiandomenico A, Keller AE, Smith TRF, Park DH, Ramos S, et al. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat Commun. 2017;8(1):637. https:\/\/doi.org\/10.1038\/s41467-017-00576-7.","journal-title":"Nat Commun"},{"issue":"11","key":"412_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1089\/hum.2019.128","volume":"30","author":"K Hollevoet","year":"2019","unstructured":"Hollevoet K, De Vleeschauwer S, De Smidt E, Vermeire G, Geukens N, Declerck P. Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep. Hum Gene Ther. 2019;30(11):1431\u201343. https:\/\/doi.org\/10.1089\/hum.2019.128.","journal-title":"Hum Gene Ther"},{"issue":"17","key":"412_CR41","doi-asserted-by":"publisher","first-page":"13623","DOI":"10.18632\/oncotarget.24426","volume":"9","author":"K Hollevoet","year":"2018","unstructured":"Hollevoet K, De Smidt E, Geukens N, Declerck P. Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies. Oncotarget. 2018;9(17):13623\u201336. https:\/\/doi.org\/10.18632\/oncotarget.24426.","journal-title":"Oncotarget"},{"issue":"7","key":"412_CR42","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.celrep.2018.10.062","volume":"25","author":"A Patel","year":"2018","unstructured":"Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, et al. In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against Ebolavirus infection in a mouse model. Cell Rep. 2018;25(7):1982\u201393. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.062(e4).","journal-title":"Cell Rep."},{"key":"412_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132779","author":"MC Wise","year":"2019","unstructured":"Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz A, Patel A, et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Investig. 2019. https:\/\/doi.org\/10.1172\/JCI132779.","journal-title":"J Clin Investig"},{"issue":"3","key":"412_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","volume":"23","author":"NY Sardesai","year":"2011","unstructured":"Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421\u20139. https:\/\/doi.org\/10.1016\/j.coi.2011.03.008.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"412_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013\u201322. https:\/\/doi.org\/10.1016\/S1473-3099(19)30266-X.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"412_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/infdis\/jiz132","volume":"220","author":"P Tebas","year":"2019","unstructured":"Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, et al. Intradermal SynCon(R) Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. J Infect Dis. 2019;220(3):400\u201310. https:\/\/doi.org\/10.1093\/infdis\/jiz132.","journal-title":"J Infect Dis"},{"key":"412_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120","author":"P Tebas","year":"2017","unstructured":"Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine\u2014preliminary report. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1708120.","journal-title":"N Engl J Med"},{"key":"412_CR48","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. https:\/\/doi.org\/10.3389\/fimmu.2019.00594.","journal-title":"Front Immunol"},{"key":"412_CR49","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630. https:\/\/doi.org\/10.1038\/ncomms14630.","journal-title":"Nat Commun"},{"issue":"7","key":"412_CR50","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mt.2012.79","volume":"20","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther. 2012;20(7):1298\u2013304. https:\/\/doi.org\/10.1038\/mt.2012.79.","journal-title":"Mol Ther"},{"issue":"4","key":"412_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"412_CR52","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340. https:\/\/doi.org\/10.1038\/mt.2008.200.","journal-title":"Mol Ther"},{"key":"412_CR53","unstructured":"Moderna. mRNA medicines to enable intracellular, membrane-bound, and extracellular secreted therapeutics. 2019. https:\/\/investors.modernatx.com\/events-and-presentations. Accessed 3 Mar 2020."},{"issue":"6","key":"412_CR54","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316\u201327. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.035.","journal-title":"Mol Ther"},{"issue":"10101","key":"412_CR55","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(17)31665-3.","journal-title":"Lancet"},{"issue":"7265","key":"412_CR56","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788\u201392. https:\/\/doi.org\/10.1038\/nature08476.","journal-title":"Nature"},{"issue":"6121","key":"412_CR57","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826\u201330. https:\/\/doi.org\/10.1126\/science.1229963.","journal-title":"Science"},{"issue":"7179","key":"412_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature06537","volume":"451","author":"KJ Ishii","year":"2008","unstructured":"Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008;451(7179):725\u20139. https:\/\/doi.org\/10.1038\/nature06537.","journal-title":"Nature"},{"issue":"11","key":"412_CR59","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.4049\/jimmunol.171.11.5908","volume":"171","author":"B Spies","year":"2003","unstructured":"Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol. 2003;171(11):5908\u201312. https:\/\/doi.org\/10.4049\/jimmunol.171.11.5908.","journal-title":"J Immunol"},{"issue":"12","key":"412_CR60","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","volume":"9","author":"T Reid","year":"2002","unstructured":"Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002;9(12):979\u201386. https:\/\/doi.org\/10.1038\/sj.cgt.7700539.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"412_CR61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1089\/hum.2012.112","volume":"24","author":"L Zhong","year":"2013","unstructured":"Zhong L, Malani N, Li M, Brady T, Xie J, Bell P, et al. Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther. 2013;24(5):520\u20135. https:\/\/doi.org\/10.1089\/hum.2012.112.","journal-title":"Hum Gene Ther"},{"issue":"5837","key":"412_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","volume":"317","author":"A Donsante","year":"2007","unstructured":"Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477. https:\/\/doi.org\/10.1126\/science.1142658.","journal-title":"Science"},{"issue":"2","key":"412_CR63","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Investig. 2015;125(2):870\u201380. https:\/\/doi.org\/10.1172\/JCI79213.","journal-title":"J Clin Investig"},{"issue":"3","key":"412_CR64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ng1179","volume":"34","author":"H Nakai","year":"2003","unstructured":"Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34(3):297\u2013302. https:\/\/doi.org\/10.1038\/ng1179.","journal-title":"Nat Genet"},{"issue":"1","key":"412_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/10430340152712665","volume":"13","author":"JN Lozier","year":"2002","unstructured":"Lozier JN, Csako G, Mondoro TH, Krizek DM, Metzger ME, Costello R, et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther. 2002;13(1):113\u201324. https:\/\/doi.org\/10.1089\/10430340152712665.","journal-title":"Hum Gene Ther"},{"key":"412_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-319-53457-2_3","volume-title":"Safety and efficacy of gene-based therapeutics for inherited disorders","author":"AW Harmon","year":"2017","unstructured":"Harmon AW, Byrnes AP. Adenovirus vector toxicity. In: Brunetti-Pierri N, editor. Safety and efficacy of gene-based therapeutics for inherited disorders. Cham: Springer International Publishing; 2017. p. 37\u201360."},{"issue":"1","key":"412_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/10430340152712629","volume":"13","author":"National Institutes of Health (NIH)","year":"2002","unstructured":"National Institutes of Health (NIH). Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002;13(1):3\u201313. https:\/\/doi.org\/10.1089\/10430340152712629.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"412_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1\u20132):148\u201358.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"412_CR69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29(3):285\u201398. https:\/\/doi.org\/10.1089\/hum.2018.015.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"412_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","volume":"36","author":"GA Rodrigues","year":"2018","unstructured":"Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NKH, Rivers HM. Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res. 2018;36(2):29. https:\/\/doi.org\/10.1007\/s11095-018-2554-7.","journal-title":"Pharm Res"},{"issue":"25","key":"412_CR71","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.074.","journal-title":"Vaccine"},{"issue":"6274","key":"412_CR72","doi-asserted-by":"publisher","first-page":"aac7247","DOI":"10.1126\/science.aac7247","volume":"351","author":"RA Elbarbary","year":"2016","unstructured":"Elbarbary RA, Lucas BA, Maquat LE. Retrotransposons as regulators of gene expression. Science. 2016;351(6274):aac7247. https:\/\/doi.org\/10.1126\/science.aac7247.","journal-title":"Science"},{"issue":"6822","key":"412_CR73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860\u2013921. https:\/\/doi.org\/10.1038\/35057062.","journal-title":"Nature"},{"issue":"1","key":"412_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrg2487","volume":"10","author":"H Kaessmann","year":"2009","unstructured":"Kaessmann H, Vinckenbosch N, Long M. RNA-based gene duplication: mechanistic and evolutionary insights. Nat Rev Genet. 2009;10(1):19\u2013311. https:\/\/doi.org\/10.1038\/nrg2487.","journal-title":"Nat Rev Genet"},{"issue":"7374","key":"412_CR75","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nature10531","volume":"479","author":"JK Baillie","year":"2011","unstructured":"Baillie JK, Barnett MW, Upton KR, Gerhardt DJ, Richmond TA, De Sapio F, et al. Somatic retrotransposition alters the genetic landscape of the human brain. Nature. 2011;479(7374):534\u20137. https:\/\/doi.org\/10.1038\/nature10531.","journal-title":"Nature"},{"key":"412_CR76","unstructured":"The Journal of Gene Medicine Clinical Trial Site. In: Gene therapy clinical trials worldwide. Wiley; 2018. https:\/\/www.abedia.com\/wiley\/index.html. Accessed 14 Aug 2019."},{"issue":"2","key":"412_CR77","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/toxsci\/kfj170","volume":"91","author":"RL Sheets","year":"2006","unstructured":"Sheets RL, Stein J, Manetz TS, Andrews C, Bailer R, Rathmann J, et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci. 2006;91(2):620\u201330. https:\/\/doi.org\/10.1093\/toxsci\/kfj170.","journal-title":"Toxicol Sci"},{"issue":"2","key":"412_CR78","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/toxsci\/kfj169","volume":"91","author":"RL Sheets","year":"2006","unstructured":"Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci. 2006;91(2):610\u20139. https:\/\/doi.org\/10.1093\/toxsci\/kfj169.","journal-title":"Toxicol Sci"},{"issue":"4","key":"412_CR79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1101\/gr.5826307","volume":"17","author":"JK Pace 2nd","year":"2007","unstructured":"Pace JK 2nd, Feschotte C. The evolutionary history of human DNA transposons: evidence for intense activity in the primate lineage. Genome Res. 2007;17(4):422\u201332. https:\/\/doi.org\/10.1101\/gr.5826307.","journal-title":"Genome Res"},{"issue":"10","key":"412_CR80","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrg2640","volume":"10","author":"R Cordaux","year":"2009","unstructured":"Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009;10(10):691\u2013703. https:\/\/doi.org\/10.1038\/nrg2640.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"412_CR81","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","volume":"107","author":"C Berger","year":"2006","unstructured":"Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107(6):2294\u2013302. https:\/\/doi.org\/10.1182\/blood-2005-08-3503.","journal-title":"Blood"},{"issue":"12","key":"412_CR82","first-page":"2697","volume":"56","author":"W Hamel","year":"1996","unstructured":"Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase\/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56(12):2697\u2013702.","journal-title":"Cancer Res"},{"issue":"5","key":"412_CR83","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1073\/pnas.93.5.1831","volume":"93","author":"M Mesnil","year":"1996","unstructured":"Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93(5):1831\u20135. https:\/\/doi.org\/10.1073\/pnas.93.5.1831.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"412_CR84","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247\u201354. https:\/\/doi.org\/10.1182\/blood-2004-11-4564.","journal-title":"Blood"},{"issue":"8","key":"412_CR85","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","volume":"13","author":"SK Tey","year":"2007","unstructured":"Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):913\u201324. https:\/\/doi.org\/10.1016\/j.bbmt.2007.04.005.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"412_CR86","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","volume":"26","author":"M Stavrou","year":"2018","unstructured":"Stavrou M, Philip B, Traynor-White C, Davis CG, Onuoha S, Cordoba S, et al. A rapamycin-activated caspase 9-based suicide gene. Mol Ther. 2018;26(5):1266\u201376. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.001.","journal-title":"Mol Ther"},{"key":"412_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","journal-title":"Front Pharmacol"},{"key":"412_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907.","journal-title":"Sci Transl Med"},{"issue":"8","key":"412_CR89","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/s41375-019-0443-7","volume":"33","author":"L Janssen","year":"2019","unstructured":"Janssen L, Frambach S, Allard NAE, Hopman MTE, Schirris TJJ, Voermans NC, et al. Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia. 2019;33(8):2116\u2013200. https:\/\/doi.org\/10.1038\/s41375-019-0443-7.","journal-title":"Leukemia"},{"issue":"5\u20136","key":"412_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41417-018-0019-0","volume":"25","author":"JA Barrett","year":"2018","unstructured":"Barrett JA, Cai H, Miao J, Khare PD, Gonzalez P, Dalsing-Hernandez J, et al. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System((R)) (RTS((R))) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther. 2018;25(5\u20136):106\u201316. https:\/\/doi.org\/10.1038\/s41417-018-0019-0.","journal-title":"Cancer Gene Ther"},{"key":"412_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","author":"EA Chiocca","year":"2019","unstructured":"Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw5680.","journal-title":"Sci Transl Med."},{"issue":"3","key":"412_CR92","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cpdd.287","volume":"6","author":"H Cai","year":"2017","unstructured":"Cai H, Sun L, Miao J, Krishman S, Lebel F, Barrett JA. Plasma pharmacokinetics of veledimex, a small-molecule activator ligand for a proprietary gene therapy promoter system. Healthy Subj Clin Pharmacol Drug Dev. 2017;6(3):246\u201357. https:\/\/doi.org\/10.1002\/cpdd.287.","journal-title":"Healthy Subj Clin Pharmacol Drug Dev"},{"issue":"1","key":"412_CR93","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1479-0556-2-2","volume":"2","author":"N Perez","year":"2004","unstructured":"Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther. 2004;2(1):2. https:\/\/doi.org\/10.1186\/1479-0556-2-2.","journal-title":"Genet Vaccines Ther"},{"issue":"3","key":"412_CR94","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymthe.2003.12.007","volume":"9","author":"TE Tjelle","year":"2004","unstructured":"Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004;9(3):328\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2003.12.007.","journal-title":"Mol Ther"},{"key":"412_CR95","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.bbrep.2015.10.007","volume":"4","author":"T Akerstrom","year":"2015","unstructured":"Akerstrom T, Vedel K, Needham J, Hojman P, Kontou E, Hellsten Y, et al. Optimizing hyaluronidase dose and plasmid DNA delivery greatly improves gene electrotransfer efficiency in rat skeletal muscle. Biochem Biophys Rep. 2015;4:342\u201350. https:\/\/doi.org\/10.1016\/j.bbrep.2015.10.007.","journal-title":"Biochem Biophys Rep"},{"issue":"16","key":"412_CR96","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/sj.gt.3301522","volume":"8","author":"JM McMahon","year":"2001","unstructured":"McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase\u2014increased expression with reduced muscle damage. Gene Ther. 2001;8(16):1264\u201370. https:\/\/doi.org\/10.1038\/sj.gt.3301522.","journal-title":"Gene Ther"},{"issue":"1","key":"412_CR97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7883\/yoken.64.40","volume":"64","author":"T Yamazaki","year":"2011","unstructured":"Yamazaki T, Nagashima M, Ninomiya D, Arai Y, Teshima Y, Fujimoto A, et al. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn J Infect Dis. 2011;64(1):40\u20139.","journal-title":"Jpn J Infect Dis"},{"issue":"Spec issue","key":"412_CR98","first-page":"9","volume":"8","author":"A Andrews","year":"2015","unstructured":"Andrews A. Treating with checkpoint inhibitors\u2014figure $1 million per patient. Am Health Drug Benefits. 2015;8(Spec issue):9.","journal-title":"Am Health Drug Benefits."},{"issue":"4","key":"412_CR99","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/hum.2018.241","volume":"30","author":"NN Schommer","year":"2019","unstructured":"Schommer NN, Nguyen J, Yung BS, Schultheis K, Muthumani K, Weiner DB, et al. Active immunoprophylaxis and vaccine augmentations mediated by a novel plasmid DNA formulation. Hum Gene Ther. 2019;30(4):523\u201333. https:\/\/doi.org\/10.1089\/hum.2018.241.","journal-title":"Hum Gene Ther"},{"issue":"22","key":"412_CR100","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-18-1429","volume":"78","author":"EK Duperret","year":"2018","unstructured":"Duperret EK, Trautz A, Stoltz R, Patel A, Wise MC, Perales-Puchalt A, et al. Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Cancer Res. 2018;78(22):6363\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1429.","journal-title":"Cancer Res"},{"key":"412_CR101","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1038\/srep12616","volume":"5","author":"S Flingai","year":"2015","unstructured":"Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis\/immunotherapy. Sci Rep. 2015;5:12616. https:\/\/doi.org\/10.1038\/srep12616.","journal-title":"Sci Rep"},{"issue":"1","key":"412_CR102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18632\/oncotarget.26535","volume":"10","author":"A Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt A, Duperret EK, Muthumani K, Weiner DB. Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs). Oncotarget. 2019;10(1):13\u20136. https:\/\/doi.org\/10.18632\/oncotarget.26535.","journal-title":"Oncotarget"},{"issue":"1","key":"412_CR103","doi-asserted-by":"publisher","first-page":"17628","DOI":"10.1038\/s41598-018-35964-6","volume":"8","author":"P Cao","year":"2018","unstructured":"Cao P, Bai H, Wang X, Che J. Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77. Sci Rep. 2018;8(1):17628. https:\/\/doi.org\/10.1038\/s41598-018-35964-6.","journal-title":"Sci Rep"},{"issue":"7","key":"412_CR104","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1080\/19420862.2018.1490119","volume":"10","author":"BJ Booth","year":"2018","unstructured":"Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, et al. Extending human IgG half-life using structure-guided design. MAbs. 2018;10(7):1098\u2013110. https:\/\/doi.org\/10.1080\/19420862.2018.1490119.","journal-title":"MAbs"},{"issue":"33","key":"412_CR105","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall'Acqua","year":"2006","unstructured":"Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514\u201324. https:\/\/doi.org\/10.1074\/jbc.M604292200.","journal-title":"J Biol Chem"},{"issue":"2","key":"412_CR106","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157\u20139. https:\/\/doi.org\/10.1038\/nbt.1601.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"412_CR107","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.4049\/jimmunol.0804182","volume":"182","author":"YA Yeung","year":"2009","unstructured":"Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol. 2009;182(12):7663\u2013711. https:\/\/doi.org\/10.4049\/jimmunol.0804182.","journal-title":"J Immunol"},{"issue":"1","key":"412_CR108","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys A, Nilsen J, Sand KMK, Daba MB, Oynebraten I, Bern M, et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621. https:\/\/doi.org\/10.1038\/s41467-018-03061-x.","journal-title":"Nat Commun"},{"issue":"1","key":"412_CR109","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","volume":"27","author":"M Khoshnejad","year":"2019","unstructured":"Khoshnejad M, Patel A, Wojtak K, Kudchodkar SB, Humeau L, Lyssenko NN, et al. Development of novel DNA-encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics. Mol Ther. 2019;27(1):188\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.016.","journal-title":"Mol Ther"},{"issue":"3","key":"412_CR110","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256\u201365. https:\/\/doi.org\/10.4161\/mabs.2.3.11641.","journal-title":"MAbs"},{"issue":"4","key":"412_CR111","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1535-7163.MCT-18-0977","volume":"18","author":"F Li","year":"2019","unstructured":"Li F, Ulrich ML, Shih VF, Cochran JH, Hunter JH, Westendorf L, et al. Mouse strains influence clearance and efficacy of antibody and antibody-drug conjugate via Fc-FcgammaR interaction. Mol Cancer Ther. 2019;18(4):780\u20137. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0977.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"412_CR112","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7182\/prtr.1.6.3.8145l3u185493182","volume":"6","author":"SL Smith","year":"1996","unstructured":"Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996;6(3):109\u201319 (quiz 20\u20131).","journal-title":"J Transpl Coord."},{"issue":"8","key":"412_CR113","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/14712598.8.8.1151","volume":"8","author":"M Boyiadzis","year":"2008","unstructured":"Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008;8(8):1151\u20138. https:\/\/doi.org\/10.1517\/14712598.8.8.1151.","journal-title":"Expert Opin Biol Ther"},{"key":"412_CR114","unstructured":"Services CgCfMM. 2019 ASP drug pricing files. In: ASP drug pricing files October 2019 update. U.S. Centers for Medicare & Medicaid Services, Baltimore, MD. 2019. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/2019ASPFiles.html#. Accessed 23 Nov 2019."},{"issue":"1","key":"412_CR115","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaoncol.2015.4191","volume":"2","author":"LB Saltz","year":"2016","unstructured":"Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2(1):19\u2013211. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4191.","journal-title":"JAMA Oncol"},{"issue":"12","key":"412_CR116","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00262-017-2042-7","volume":"66","author":"K Muthumani","year":"2017","unstructured":"Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunol Immunother. 2017;66(12):1577\u201388. https:\/\/doi.org\/10.1007\/s00262-017-2042-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"412_CR117","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"key":"412_CR118","unstructured":"Administration USFaD. Drugs@FDA: FDA Approved Drug Products. U.S. FDA, Silver Springs, MD. 2019. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed 23 Nov 2019."},{"key":"412_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126086","author":"A Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt A, Duperret EK, Yang X, Hernandez P, Wojtak K, Zhu X, et al. DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.126086.","journal-title":"JCI Insight."},{"issue":"7","key":"412_CR120","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler CR, Bahr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23(7):815\u20137. https:\/\/doi.org\/10.1038\/nm.4356.","journal-title":"Nat Med"},{"issue":"3","key":"412_CR121","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/infdis\/jiw111","volume":"214","author":"K Muthumani","year":"2016","unstructured":"Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis. 2016;214(3):369\u201378. https:\/\/doi.org\/10.1093\/infdis\/jiw111.","journal-title":"J Infect Dis"},{"issue":"1","key":"412_CR122","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/imr.12478","volume":"275","author":"JM Brady","year":"2017","unstructured":"Brady JM, Baltimore D, Balazs AB. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev. 2017;275(1):324\u201333. https:\/\/doi.org\/10.1111\/imr.12478.","journal-title":"Immunol Rev"},{"key":"412_CR123","unstructured":"Prevention CfDCa. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States\u20142017\u20132018 influenza season. In: Influenza (Flu). Centers for Disease Control and Prevention, Atlanta, GA. 2019. https:\/\/www.cdc.gov\/flu\/about\/burden\/2017-2018.htm. Accessed 23 November 2019."},{"issue":"15","key":"412_CR124","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"RT Davey Jr","year":"2016","unstructured":"Group PIW, Multi-National PIIST, Davey RT Jr, Dodd L, Proschan MA, Neaton J, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375(15):1448\u2013566. https:\/\/doi.org\/10.1056\/NEJMoa1604330.","journal-title":"N Engl J Med."},{"issue":"3","key":"412_CR125","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ije\/dyw366","volume":"46","author":"AJ Alaniz","year":"2017","unstructured":"Alaniz AJ, Bacigalupo A, Cattan PE. Spatial quantification of the world population potentially exposed to Zika virus. Int J Epidemiol. 2017;46(3):966\u201375. https:\/\/doi.org\/10.1093\/ije\/dyw366.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"412_CR126","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 2018;19(11):1179\u201388. https:\/\/doi.org\/10.1038\/s41590-018-0235-7.","journal-title":"Nat Immunol"},{"key":"412_CR127","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647","author":"N Kose","year":"2019","unstructured":"Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019. https:\/\/doi.org\/10.1126\/sciimmunol.aaw6647.","journal-title":"Sci Immunol."},{"key":"412_CR128","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-981-13-0484-2_3","volume":"1075","author":"X Wu","year":"2018","unstructured":"Wu X. HIV broadly neutralizing antibodies: VRC01 and beyond. Adv Exp Med Biol. 2018;1075:53\u201372. https:\/\/doi.org\/10.1007\/978-981-13-0484-2_3.","journal-title":"Adv Exp Med Biol"},{"key":"412_CR129","unstructured":"Prevention CfDCa. Lyme disease: data and surveillance. Centers for Disease Control and Prevention. 2019. https:\/\/www.cdc.gov\/lyme\/datasurveillance\/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html. Accessed 14 Aug 2019."},{"issue":"7","key":"412_CR130","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/infdis\/jiy627","volume":"219","author":"Y Wang","year":"2019","unstructured":"Wang Y, Esquivel R, Flingai S, Schiller ZA, Kern A, Agarwal S, et al. Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice. J Infect Dis. 2019;219(7):1146\u201350. https:\/\/doi.org\/10.1093\/infdis\/jiy627.","journal-title":"J Infect Dis"},{"issue":"20","key":"412_CR131","first-page":"5845","volume":"62","author":"JM Timmerman","year":"2002","unstructured":"Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62(20):5845\u201352.","journal-title":"Cancer Res"},{"issue":"4","key":"412_CR132","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019;6(4):e230\u2013e239239. https:\/\/doi.org\/10.1016\/S2352-3018(19)30003-7.","journal-title":"Lancet HIV"}],"updated-by":[{"DOI":"10.1007\/s40259-020-00424-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00412-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-020-00412-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00412-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T05:32:44Z","timestamp":1666071164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-020-00412-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00412-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-020-00424-z","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"10 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies, written by Ami Patel, Mamadou A. Bah and David B.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are grateful for funding from The Bill and Melinda Gates Foundation (OPP1163327 and OPP1201239 award to David B. Weiner) and National Institutes of Health (R01 AI141236 award to David B. Weiner and U19 AI142777 subaward to Ami Patel). The research described in this manuscript was funded by The Bill and Melinda Gates Foundation (OPP1163327 and OPP1201239 award to David B. Weiner).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. B. declares no competing interests. A. P. is listed as an inventor on patents related to DMAbs. D. B. W. has received grant funding, participates in industry collaborations, has received speaking honoraria, and has received fees for consulting, including serving on scientific review committees and board service. Remuneration received by D. B. W. includes direct payments or stock or stock options, and, in the interest of disclosure, he notes potential conflicts associated with this work with Inovio and possibly others. In addition, he has patents on DMAbs and DNA vaccine delivery.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}